{"classes":[{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual titer value for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual titer value for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"400.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"End of Treatment (~157 weeks)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were further tested in screening assay, and positive samples were further characterized for antibody titers.","dispersionType":"Full Range","groups":[{"description":"In CE Phase, Participants with RRMM received 0.95 mg/ kg belantamab mafodotin IV infusion as powder for solution once every 3 weeks (Q3W), infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG000","title":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat"},{"description":"In CE Phase, Participants with RRMM received 2.5 mg/ kg belantamab mafodotin IV infusion as powder for solution Q3W, infused over 30- 60 minutes on day 1 of 21-day cycles until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG001","title":"CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W"}],"paramType":"MEDIAN","populationDescription":"Safety Population. Only those participants with positive ADA data available at the specified timepoint is presented.","reportingStatus":"POSTED","timeFrame":"C2 D1 and at End of Treatment (approximately 157 weeks)","title":"CE Phase: Titer of ADAs Against Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"Titer"}